Ocumension Therapeutics-B (01477.HK): Topline results of the primary analysis at month 36 of the global multicenter Phase III clinical trial of OT-101 (0.01% atropine sulfate eye drops)

Zhitong Finance APP News, Ocumension Therapeutics-B (01477.HK) announced that OT-101 (0.01% atropine sulfate eye drops) is a low-concentration (0.01%) atropine eye drop independently developed by the Group, used to delay or slow the progression of myopia in children and adolescents. However, the instability of low-concentration atropine solutions has long been a technical obstacle to commercialization. OT-101 uses an exclusively designed innovative sealed split device, which solves the stability problem of low-concentration atropine solutions in a neutral environment. The suitable pH value also improves patient comfort during medication and enhances medication compliance.